L. Åström

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer

U. Isacsson, I. Turesson, A. Montelius, 2012, Prostate cancer.

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.

P. Kellokumpu-Lehtinen, T. Huttunen, C. Thellenberg-Karlsson, 2019, European urology.

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.

V. Matveev, E. Senkus, A. Merseburger, 2022, The Lancet. Oncology.

Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer.

L. Holmberg, L. Åström, F. Sandin, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Dose Escalation with High Dose Rate Brachytherapy or Protons in Curative Radiotherapy of Prostate Cancer

L. Åström, 2018 .

Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer.

K. Johansson, S. Holmäng, C. Mercke, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer.

L. Holmberg, I. Turesson, L. Åström, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study

P. Stattin, A. Pettersson, P. Nilsson, 2020, JNCI cancer spectrum.

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

P. Kellokumpu-Lehtinen, M. Taalikka, C. Thellenberg-Karlsson, 2012, Prostate Cancer and Prostatic Diseases.

High-dose-rate brachytherapy in prostate cancer. The first experience in Norway

W. Lilleby, L. Åström, N. Raabe, 2015 .